Jadenu

Chronic Iron Overload from Blood Transfusions

Jadenu is used to treat chronic iron overload in adults and children 2 years of age and older who receive frequent blood transfusions. This condition, known as transfusional hemosiderosis, can occur in people with chronic anemias such as sickle cell disease, thalassemia, or myelodysplastic syndromes. Because the body has no natural way to remove excess iron gained from transfused blood, the iron can build up over time and potentially damage organs like the heart and liver.

Chronic Iron Overload in Thalassemia

This medication is also used to treat chronic iron overload in adults and children 10 years of age and older who have non-transfusion-dependent thalassemia (NTDT) syndromes. In these conditions, the body may absorb too much iron from food even without regular transfusions, leading to high iron levels that require treatment.

Jadenu belongs to a class of drugs called iron chelators. It works by binding to excess iron in the bloodstream and tissues, which then allows the body to pass the iron out through the stool.

Removing Excess Iron

Jadenu contains the active ingredient deferasirox, which belongs to a class of medications called iron-chelating agents. Its primary function is to reduce high levels of iron in the body, a condition often caused by frequent blood transfusions or certain genetic blood disorders.

The Chelation Process

The medication works through a process called chelation:

• Binding: Once ingested, the medicine travels through the bloodstream and attaches itself to excess iron molecules.
• Neutralizing: By binding to the iron, the medication prevents the extra iron from damaging organs such as the liver and heart.
• Elimination: The combined complex of the medicine and the iron is then processed by the body and primarily excreted through the stool (feces).

By helping the body get rid of this extra iron, Jadenu helps bring iron levels back toward a normal range and prevents the long-term complications associated with chronic iron overload.

Common Side Effects

The most frequently reported side effects of Jadenu include:

• Nausea, vomiting, or diarrhea
• Stomach pain
• Skin rash or itching
• Headache
• Fever, cough, or sore throat

Serious Side Effects

Jadenu can cause severe or life-threatening side effects. Seek medical attention immediately for:

• Kidney issues: Changes in how much you urinate or swelling in your feet and ankles.
• Liver issues: Yellowing of the skin or eyes, dark-colored urine, or pain in the upper right abdomen.
• Gastrointestinal bleeding: Stools that are black, bloody, or tarry, or vomiting blood.
• Sensory changes: Blurred vision, changes in how you see colors, or hearing loss.
• Severe skin reactions: Skin pain followed by a red or purple rash that blisters and peels.
• Blood cell changes: Signs of infection such as fever, or unusual bruising and bleeding.

Boxed Warning

Jadenu can cause serious and potentially life-threatening side effects, including kidney failure, liver failure, and bleeding in the stomach or intestines. These risks are higher in elderly patients or those with pre-existing medical conditions. Monitoring of kidney and liver function is required before and during treatment.

Kidney and Liver Health

Treatment may lead to acute kidney failure or significant increases in serum creatinine levels. Liver failure and elevations in liver enzymes or bilirubin have also been reported. Healthcare providers typically perform blood and urine tests before starting treatment and at regular intervals during therapy to monitor organ health. Dose adjustments or treatment suspension may be necessary if function declines.

Gastrointestinal Risks

Severe gastrointestinal issues, such as ulcers, perforations, and bleeding, can occur. These complications may happen without warning and can be fatal. Caution is advised for individuals with a history of stomach problems or those taking medications that increase bleeding risk, such as anticoagulants or nonsteroidal anti-inflammatory drugs (NSAIDs).

Blood Disorders

Jadenu may cause low blood cell counts, including anemia, low white blood cell counts (leukopenia), and low platelet counts (thrombocytopenia). Regular blood tests are used to monitor for these changes, and treatment may be interrupted if blood counts fall too low.

Skin and Hypersensitivity Reactions

Serious skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported. Treatment is typically stopped if a severe rash or hypersensitivity reaction occurs.

Vision and Hearing Changes

Some patients may experience changes in hearing or vision, such as cataracts or retinal disorders. Periodic eye and ear examinations are often recommended during long-term use.

Contraindications

• Severe kidney impairment (creatinine clearance less than 40 mL/min).
• High-risk myelodysplastic syndromes.
• Advanced malignancies.
• Low platelet counts (less than 50 x 10^9/L).
• Known hypersensitivity to deferasirox or any of its components.

Pregnancy

There are no adequate and well-controlled studies of Jadenu in pregnant women. In animal studies, the medication was associated with developmental toxicity, including skeletal variations and decreased fetal body weight, at doses lower than the maximum recommended human dose. Because of these potential risks, Jadenu should be used during pregnancy only if the potential benefit to the mother outweighs the potential risk to the unborn baby.

Contraception

Jadenu may decrease the effectiveness of hormonal contraceptives, such as birth control pills, patches, or implants. Individuals who can become pregnant should discuss using additional or alternative non-hormonal methods of contraception with their healthcare provider while taking this medication.

Breastfeeding

It is not known whether Jadenu is excreted in human breast milk. Because many drugs are passed through milk and there is a potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue breastfeeding or discontinue the drug. This decision should take into account the importance of the medication to the mother's health.

Available Forms

Jadenu is provided in the following oral formulations:

• Film-coated tablets: These tablets are intended to be swallowed whole.
• Sprinkle granules: This formulation consists of granules provided in sachets. The granules are meant to be sprinkled on soft foods, such as applesauce or yogurt, for administration.

Jadenu is a different formulation of deferasirox than the dispersible tablets sold under other brand names. These different formulations are not interchangeable.

FDA Approval and Indications

Jadenu (deferasirox) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic iron overload. It is available in two specific indications:

• Transfusional Iron Overload: For patients 2 years of age and older who have developed chronic iron overload due to frequent blood transfusions (hemosiderosis).
• Non-Transfusion-Dependent Thalassemia (NTDT): For patients 10 years of age and older with chronic iron overload caused by thalassemia syndromes that do not require regular transfusions.

Jadenu was approved as a film-coated tablet and granule formulation to provide a more convenient dosing option compared to earlier dispersible tablet versions of deferasirox.

Boxed Warning

The FDA has issued a Boxed Warning for Jadenu due to the risk of severe and potentially fatal adverse reactions. These risks include:

• Renal Failure: Acute kidney failure and death have been reported. Kidney function must be monitored closely during therapy.
• Hepatic Failure: Severe liver toxicity and liver failure, sometimes resulting in death, have occurred. Liver function tests are required before starting and during treatment.
• Gastrointestinal Hemorrhage: Serious and fatal gastrointestinal bleeding has been reported, particularly in elderly patients and those with advanced blood-related cancers or low platelet counts.

Regulatory Requirements and Monitoring

Due to these risks, the FDA requires regular laboratory monitoring for all patients. This includes baseline and periodic testing of serum creatinine, creatinine clearance, and liver transaminases. Jadenu is contraindicated in patients with severe renal impairment, high-risk myelodysplastic syndromes, or advanced malignancies.

Generic Availability

Jadenu is a brand name for the drug deferasirox. Generic versions of deferasirox tablets are available and may be a more affordable option than the brand-name product. You should consult with your healthcare provider or pharmacist to determine if a generic version is appropriate for your treatment.

Factors Influencing Price

Several factors can impact the final cost of Jadenu:

• Insurance Coverage: Your out-of-pocket expenses will vary based on your health insurance plan's formulary, deductible, and copayment or coinsurance requirements.
• Dosage and Quantity: Jadenu is available in different strengths (90 mg, 180 mg, and 360 mg). The total cost is affected by the specific strength and the number of tablets required for your daily dose.
• Specialty Pharmacy: Because Jadenu is a specialized medication, it is often dispensed through specialty pharmacies rather than standard retail pharmacies. These pharmacies may have specific pricing and delivery arrangements with insurance providers.

Financial Assistance Programs

Financial assistance may be available for patients who have difficulty affording their medication. The manufacturer of Jadenu and various non-profit organizations sometimes offer patient assistance programs or copay cards to help reduce costs for eligible individuals. Your doctor or a specialty pharmacy coordinator can often provide information on how to apply for these programs.